BioMarin Pharmaceutical (BMRN) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TG Therapeutics (TGTX) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 58.3% versus a gain of 1.8%. Over five years, TGTX leads with a +66.2% price change compared with -27.8% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($10.61 billion vs $8.48 billion), about 1.3 times the size, while TG Therapeutics is growing revenue faster (+87.3% vs +12.9%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 20.4x for TG Therapeutics). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus 10.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | TGTX |
|---|---|---|
| Share price | $54.80 | $55.37 |
| Market cap | $10.61B | $8.48B |
| 1-day change | -0.17% | +3.81% |
| YTD return | -7.80% | +85.74% |
| 1-year return | +1.75% | +58.34% |
| 5-year return | -27.80% | +66.23% |
| P/E ratio (TTM) | 148.09 | 20.13 |
| Forward P/E | 8.26 | 20.45 |
| EPS (TTM) | $0.37 | $2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $616.29M |
| Revenue growth (YoY) | +12.87% | +87.32% |
| Net income (latest FY) | $348.90M | $447.18M |
| Gross margin | 77.73% | 83.66% |
| Operating margin | 12.71% | 20.01% |
| Net margin | 10.83% | 72.56% |
| 52-week high | $70.98 | $59.30 |
| 52-week low | $49.26 | $26.76 |
| Distance from 52-week high | -22.80% | -6.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.21% | +25.90% |
| Average volume | 2.05M | 2.02M |
| Shares outstanding | 193.57M | 153.08M |
| Employees | 3,221 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed BMRN by 56.6 percentage points over the past year.
- BioMarin Pharmaceutical trades at a higher earnings multiple (148.1x vs 20.1x trailing P/E).
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus 10.8 cents for BioMarin Pharmaceutical.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +12.87%).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
BMRN vs TGTX FAQ
Which is bigger, BioMarin Pharmaceutical or TG Therapeutics?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $10.61B compared with $8.48B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, BMRN or TGTX?
TGTX returned +58.34% over the past 12 months, compared with +1.75% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMRN or TGTX?
TGTX has the lower trailing P/E at 20.1, versus 148.1 for BMRN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BioMarin Pharmaceutical and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.